Details

Autor(en) / Beteiligte

• Kocsmár, Ildikó
• Pajor, Gábor
• Gyöngyösi, Benedek
• Székely, Eszter
• Varga, Márton
• Kocsmár, Éva
• Kenessey, István
• Beöthe, Tamás
• Süle, Norbert
• Majoros, Attila
• Szendrői, Attila
• Nyírády, Péter
• Kiss, András
• Riesz, Péter
• Lotz, Gábor

Titel

Development and Initial Testing of a Modified UroVysion-Based Fluorescence In Situ Hybridization Score for Prediction of Progression in Bladder Cancer

Ist Teil von

• American journal of clinical pathology, 2020-01, Vol.153 (2), p.274-284

Ort / Verlag

US: Oxford University Press

Erscheinungsjahr

2020

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Abstract Objectives Our aim was to predict progression of non-muscle-invasive bladder urothelial carcinomas (NMIUCs) into muscle-invasive disease by assessing cytogenetic abnormality of tumors with a new UroVysion scoring system. Methods Seventy-five bladder cancer cases (including 57 NMIUCs) were classified according to the quantitatively assessed degree of UroVysion-detected chromosomal abnormalities into urine fluorescence in situ hybridization score (UFS) groups: UFS I, II, and III. Cox time-to-event, Kaplan-Meier, and C-statistics analyses were performed. Results UFS proved to be an independent prognostic factor of progression-free survival (PFS) and time to progression (TTP). NMIUCs with UFS III had a 34.05-fold increased hazard for progression to muscle-invasive cancer (TTP; 95% confidence interval, 5.841-198.5; P < .001) in comparison with UFS I to II cases. The addition of UFS to conventional risk scores increased the C-index for PFS and TTP. Conclusions UFS can indicate an increased risk for progression into muscle-invasive disease in patients with NMIUC and improves prognostic accuracy of the current clinical risk assessment systems.